Frequent overexpression of ROR1 in triple-negative breast cancer

Breast cancer is not a single disease but a collection of different conditions, each behaving in its own way. Among these, triple-negative breast cancer is one of the most difficult to treat. It is called "triple-negative" because the cancer cells lack three specific receptors that doctors usually target with medication: estrogen, progesterone, and HER2. Without these targets, standard hormone therapies and many common drugs do not work, leaving patients with fewer options, especially when the cancer spreads to other parts of the body. Scientists have been searching for new ways to attack these aggressive tumors, looking for unique markers on the surface of the cancer cells that could serve as a handle for new treatments. One such marker is a protein called ROR1. In a healthy adult body, this protein is mostly silent, but in many types of cancer, it wakes up and helps the tumor grow and spread. Understanding where and how much of this protein appears could be the key to designing better therapies for patients who have run out of options.

Researchers at the Sun Yat-sen University Cancer Center set out to map the presence of this ROR1 protein in patients with triple-negative breast cancer. They wanted to know if the protein was more common in the original tumor or if it became more abundant when the cancer spread to other organs. To find the answer, they gathered tissue samples from 148 patients who had been diagnosed with the disease. For 49 of these patients, the team had the rare opportunity to compare two samples from the same person: the original tumor found in the breast and a sample taken from a metastatic lesion, which is a new tumor that had formed elsewhere in the body. Using a standard laboratory technique that stains tissue to reveal specific proteins, the scientists examined these samples under a microscope. They counted how many cells displayed the ROR1 protein and measured how strongly it appeared. They also looked for immune cells, specifically T-cells, which are the body's natural soldiers that try to fight off cancer, to see if the presence of ROR1 changed the environment around the tumor.

The results revealed a striking pattern. The researchers found that the ROR1 protein was present in about two-thirds of the metastatic lesions, appearing in 66.9 percent of the samples taken from spreading tumors. More importantly, when they compared the original breast tumors to the metastatic ones from the same patients, the cancer cells in the metastatic sites showed significantly higher levels of ROR1. In nearly half of the paired samples, the protein was either absent or weak in the original tumor but clearly present and strong in the spread. This suggests that as the cancer moves through the body, it may be turning up the volume on this specific protein. The team also discovered that patients whose tumors did not have this protein tended to live longer and stay cancer-free for a longer time compared to those with high levels of ROR1. In fact, the presence of the protein was a strong indicator of a poorer outcome, regardless of whether the sample came from the original site or a distant one.

Beyond just the cancer cells themselves, the study uncovered a surprising connection between this protein and the immune system. In tumors with high levels of ROR1, the researchers found a much higher density of CD3 and CD8 T-cells. These are specific types of white blood cells that can recognize and kill cancer cells. It is somewhat counterintuitive that a protein linked to worse survival would be found alongside an army of immune cells, but the data showed that the more ROR1 present, the more T-cells were packed into the tumor. This was true for both the original and the metastatic tumors, though the immune presence was even stronger in the metastatic sites. To understand exactly which cells were holding the ROR1 protein, the team analyzed genetic data from single cells, a method that looks at the activity of individual cells rather than a whole lump of tissue. This analysis confirmed that in metastatic samples, the ROR1 protein was concentrated heavily within the malignant cancer cells themselves, rather than in the surrounding healthy tissue.

The study also noted that this pattern held true even when looking at a specific subgroup of patients whose tumors had low levels of HER2, a different type of receptor. In these cases, the metastatic tumors were even more likely to show ROR1 expression than the primary tumors. While the researchers could not definitively prove why the protein increases as the cancer spreads, their findings align with the idea that ROR1 helps cancer cells become more aggressive and resistant to treatment. The team acknowledged that their work was based on a single hospital and a relatively small number of patients, so the results need to be confirmed by larger studies. However, the consistency of the findings offers a clear direction for the future. Because the protein is so prevalent in the most dangerous, spreading forms of the disease, and because new drugs designed to target ROR1 are already being tested, these results suggest that focusing on this protein could be a vital strategy. For patients with triple-negative breast cancer, especially those with metastatic disease, targeting ROR1 might offer a new way to stop the cancer where it is most active.